Tacrolimus Ointment in Periorbital Atopic Dermatitis.
atopic dermatitis
immunomodulatory
topical corticosteroid
topical tacrolimus
vernal keratoconjunctivitis (vkc)
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
accepted:
27
01
2024
medline:
27
2
2024
pubmed:
27
2
2024
entrez:
27
2
2024
Statut:
epublish
Résumé
Periorbital atopic dermatitis (AD) is a common sign in ophthalmological practice and usually has a persistent and relapsing course. Treatment with topical corticosteroids has various side effects associated with their usage. Tacrolimus topical ointment has unique immunomodulatory properties that decrease skin inflammation and pruritus in AD. In this case series, we present a prospective case series of five patients (three males and two females) who received topical application of tacrolimus ointment 0.1-0.03% in the periorbital area twice daily for one to four weeks. The pre- and post-treatment images of all patients were recorded to compare the effects of the treatment. The cases were selected from patients attending the outpatient clinics of East Jeddah Hospital, Saudi Arabia. All patients were suffering from AD. Patients underwent a clinical assessment by tactile inspection (location, size, color, and surface condition) in the first week, secondweek, third month, and first year. We may conclude from this study that tacrolimus showed promising outcomes and is safe and effective for the treatment of flares or resistant periorbital AD in both adults and children.
Identifiants
pubmed: 38410340
doi: 10.7759/cureus.53055
pmc: PMC10896248
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e53055Informations de copyright
Copyright © 2024, Alzahrani et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.